Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty

St. Luke's Episcopal Hospital, Texas Heart Institute, Baylor College of Medicine, Houston 77225.

OBJECTIVES. The purpose of this study was to determine whether a low procedural activated coagulation time is associated with a high rate of in-hospital complications and to identify whether there is an activated coagulation time range that may be associated with a low rate of complications. BACKGROUND. In recent years the activated coagulation time has come into widespread use for monitoring anticoagulation in the catheterization laboratory. However, considerable controversy exists as to the standards by which to judge "adequate" anticoagulation for interventional procedures. METHODS. From a total of 1,469 consecutive patients with percutaneous transluminal coronary angioplasty, we retrospectively identified 103 (Group I, 7% of the overall population) with major complications of death or emergency or urgent coronary artery bypass graft surgery and compared them with 400 patients without complications (Group II). Group I patients had more high risk clinical characteristics, such as type B and C lesions, class III and IV angina, recent myocardial infarction and recent thrombolytic treatment. Activated coagulation times were compared between Groups I and II at baseline, after administration of 10,000 U of heparin and at the end of the procedure. RESULTS. There were no differences in baseline activated coagulation times between Groups I and II. Group I had significantly lower activated coagulation times after heparin therapy and at the end of the procedure: 61% < 250 s, 20% between 250 and 275 s, 11% between 275 and 300 s and 8% > 300 s; 279 of Group II had activated coagulation times 27% < 250 s, 17% between 250 and 275 s, 35% between 275 and 300 s and 21% > 300 s (p < 0.0001). Complications occurred in all patients with final activated coagulation times < 250 s but in only 0.3% of patients with final activated coagulation times > 300 s. CONCLUSIONS. A diminished activated coagulation time response to an initial bolus of heparin is associated with major in-hospital complications after coronary angioplasty, although patients with complications did have a higher risk before the procedure. It remains to be determined whether there is an ideal "target" activated coagulation time for interventional procedures.

This article has been cited by other articles:

				R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]

				F. Andreotti and R. C. Becker Atherothrombotic Disorders: New Insights From Hematology Circulation, April 12, 2005; 111(14): 1855 - 1863. [Full Text] [PDF]

				J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]

				S. J. Brener, D. J. Moliterno, A. M. Lincoff, S. R. Steinhubl, K. E. Wolski, and E. J. Topol Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications: Analysis of 4 Recent Randomized Clinical Trials of Percutaneous Coronary Intervention Circulation, August 24, 2004; 110(8): 994 - 998. [Abstract] [Full Text] [PDF]

				M. Tobu, O. Iqbal, H. L. Messmore, Q. Ma, D. A. Hoppensteadt, and J. Fareed Influence of Different Anticoagulant Agents on Fibrinopeptide A Generation Clinical and Applied Thrombosis/Hemostasis, October 1, 2003; 9(4): 273 - 292. [Abstract] [PDF]

				T. R. Tolleson, J. C. O'Shea, J. A. Bittl, W. B. Hillegass, K. A. Williams, G. Levine, R. A. Harrington, and J. E. Tcheng Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial J. Am. Coll. Cardiol., February 5, 2003; 41(3): 386 - 393. [Abstract] [Full Text] [PDF]

				G Niccoli and A P Banning Heparin dose during percutaneous coronary intervention: how low dare we go? Heart, October 1, 2002; 88(4): 331 - 334. [Abstract] [Full Text] [PDF]

				S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239. [Full Text] [PDF]

				J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention Chest, January 1, 2001; 119(1_suppl): 321S - 336S. [Full Text] [PDF]

				H. Emanuelsson Stents, antithrombotic agents and vascular complications. Does site of arterial access make a difference? Eur. Heart J., April 2, 2000; 21(8): 607 - 609. [PDF]

				M. Rabah, D. Mason, D. W. M. Muller, R. Hundley, A. D. Kugelmass, B. Weiner, L. Cannon, W. W. O'Neill, and R. D. Safian Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention J. Am. Coll. Cardiol., August 1, 1999; 34(2): 461 - 467. [Abstract] [Full Text] [PDF]

				A. D. Kugelmass and G. E. Raskob Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty or Coronary Stent Placement Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(1_suppl): S24 - S31. [PDF]

				L. Oltrona, P. R. Eisenberg, J. M. Lasala, D. J. Sewall, M. E. Shelton, and K. J. Winters Association of Heparin-Resistant Thrombin Activity With Acute Ischemic Complications of Coronary Interventions Circulation, November 1, 1996; 94(9): 2064 - 2071. [Abstract] [Full Text]

				C. R. Narins, W. B. Hillegass Jr, C. L. Nelson, J. E. Tcheng, R. A. Harrington, H. R. Phillips, R. S. Stack, and R. M. Califf Relation Between Activated Clotting Time During Angioplasty and Abrupt Closure Circulation, February 15, 1996; 93(4): 667 - 671. [Abstract] [Full Text]